Drug Patents owned by Chemocentryx

1. List of Tavneos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8906938 CHEMOCENTRYX C5aR antagonists
Dec, 2029

(6 years from now)

US8445515 CHEMOCENTRYX C5aR antagonists
Feb, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2028
New Chemical Entity Exclusivity (NCE) Oct 7, 2026

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: October, 2025

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in